American Century Companies’s Bicara Therapeutics BCAX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.46M Buy
82,716
+31,163
+60% +$695K ﹤0.01% 2138
2026
Q1
$1.03M Buy
51,553
+27,060
+110% +$466K ﹤0.01% 2319
2025
Q4
$412K Buy
24,493
+13,816
+129% +$236K ﹤0.01% 2558
2025
Q3
$169K Sell
10,677
-419
-4% -$4.69K ﹤0.01% 2712
2025
Q2
$103K Buy
+11,096
New +$132K ﹤0.01% 2793

Other funds holding BCAX

American Century Companies's BCAX Position: Q2 2026 in Review

American Century Companies increased its Bicara Therapeutics (BCAX) stake by 60% in Q2 2026, buying an estimated $695K and bringing the position to 82,716 shares worth $2.46M. The position accounts for ﹤0.01% of the portfolio, ranked #2138.

American Century Companies first reported a position in BCAX in Q2 2025 and has held it in 5 quarters since. 112 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • American Century Companies held 82,716 shares of Bicara Therapeutics worth $2.46M as of Q2 2026.
  • American Century Companies bought 31,163 Bicara Therapeutics shares in Q2 2026, an estimated $695K.
  • Bicara Therapeutics made up ﹤0.01% of American Century Companies's portfolio in Q2 2026, its #2138 holding.
  • American Century Companies first reported a position in Bicara Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 112 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on American Century Companies's 13F filing for Q2 2026, filed 12 Aug 2026.